Zobrazeno 1 - 10
of 209
pro vyhledávání: '"Helgi VAN DE VELDE"'
Autor:
Kamlesh Bisht, Aimee Merino, Rob Igarashi, Laurent Gauthier, Marielle Chiron, Alexandre Desjonqueres, Eric Smith, Edward Briercheck, Rizwan Romee, Evren Alici, Eric Vivier, Michael O’Dwyer, Helgi van de Velde
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-18 (2024)
Abstract Despite therapeutic advancements, multiple myeloma (MM) remains incurable. NK cells have emerged as a promising option for the treatment of MM. NK cells are heterogenous and typically classified based on the relative expression of their surf
Externí odkaz:
https://doaj.org/article/0b35578717bf4584af3e0678d86f8cc2
Autor:
Kamlesh Bisht, Taro Fukao, Marielle Chiron, Paul Richardson, Djordje Atanackovic, Eduardo Chini, Wee Joo Chng, Helgi Van De Velde, Fabio Malavasi
Publikováno v:
Cancer Medicine, Vol 12, Iss 20, Pp 20332-20352 (2023)
Abstract Background CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors
Externí odkaz:
https://doaj.org/article/11c9e5f0da7846b4a4ba574aa7ba86ce
Autor:
Anna Luise Grab, Peter S. Kim, Lukas John, Kamlesh Bisht, Hongfang Wang, Anja Baumann, Helgi Van de Velde, Irene Sarkar, Debarati Shome, Philipp Reichert, Calin Manta, Stefanie Gryzik, Rogier M. Reijmers, Niels Weinhold, Marc S. Raab
Publikováno v:
Cells, Vol 13, Iss 10, p 879 (2024)
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates CD3 a
Externí odkaz:
https://doaj.org/article/8503b9abaeac4cfa9e1744711dde30b6
Autor:
Aurore Perrot, Paul Richardson, Joseph Mikhael, Thomas G. Martin, Meral Beksac, Ivan Spicka, Marcelo Eduardo Capra, Mattia D’agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau
Publikováno v:
HemaSphere, Vol 7, p e3398301 (2023)
Externí odkaz:
https://doaj.org/article/5bf02ff2dab540669ea5d09505ce72e3
Autor:
Patrick Reville, Enyu Dai, Irtiza Sheikh, Qing Deng, Jared Henderson, Cuong Le, Estela Rojas, Chizitara Okwuchi, Ashley Wilson, Sydney Parsons, Shyanne Lockman, Peter Kim, Kamlesh Bisht, Helgi van de Velde, Hongfang Wang, Sattva Neelapu, Linghua Wang, Michael Green
Publikováno v:
HemaSphere, Vol 7, p e860097f (2023)
Externí odkaz:
https://doaj.org/article/f26e3366b46d4c408ef5029fcaa5172c
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)
Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini
Externí odkaz:
https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e
Autor:
Tom Martin, Paul G Richardson, Thierry Facon, Philippe Moreau, Aurore Perrot, Ivan Spicka, Kamlesh Bisht, Marlene Inchauspé, France Casca, Sandrine Macé, Helgi van de Velde, Kenshi Suzuki
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
Externí odkaz:
https://doaj.org/article/ef5c6c0a96fa4f00a16ff07ee21c4c89
Autor:
Paul G. Richardson, Thierry Facon, William I. Bensinger, Xavier Leleu, Frank Campana, Sandrine Macé, Marielle Chiron, Helgi van de Velde, Joseph Mikhael
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-5 (2021)
Externí odkaz:
https://doaj.org/article/31f3b839f54a49c8a076edc5d8cd9bc3
Autor:
Fredrik Schjesvold, Paul G. Richardson, Thierry Facon, Adrián Alegre, Andrew Spencer, Artur Jurczyszyn, Kazutaka Sunami, Laurent Frenzel, Chang-Ki Min, Sophie Guillonneau, Peggy L. Lin, Solenn Le-Guennec, Frank Campana, Helgi van de Velde, Samira Bensfia, Sara Bringhen
Publikováno v:
Haematologica, Vol 107, Iss 3 (2022)
Externí odkaz:
https://doaj.org/article/0924eb46930d43269978117cdfa7df34
Autor:
Mehmut TURGUT, Roman HAJEK, Tomas JELÍNEK, Philippe MOREAU, Thomas MARTIN, Ludek POUR, Gabor MIKALA, Argiris SYMEONIDIS, Sara BRINGHEN, Andreea RAWLINGS, Marie Laure RISSE, Helgi VAN DE VELDE, Ivan SPICKA
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S18- (2021)
Objective: Phase 3 IKEMA study (NCT03275285) showed significant improvement in PFS with Isatuximab (Isa) + carfilzomib (K) and dexamethasone (d) vs Kd in patients (pts) with relapsed multiple myeloma (MM) (HR: 0.531; 99% CI: 0.32–0.89; P=0.0007), l
Externí odkaz:
https://doaj.org/article/3c2d6faeced74604914a15ac633f598e